Article
Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.
Translational research : the journal of laboratory and clinical medicine - 1 May 2023
An Lei, Wang Yueqiang, Wu Guangyao, Wang Zhenxing, Shi Zeyuan, Liu Chang, Wang Chunli, Yi Ming, Niu Chenguang, Duan Shaofeng, Li Xiaodong, Tang Wenxue, Wu Kongming, Chen Shuqing, Xu Hongen
Abstract excerpt
Tyrosine kinase inhibitor (TKI) is a standard treatment for patients with NSCLC harboring constitutively active epidermal growth factor receptor (EGFR) mutations. However, most rare EGFR mutations lack treatment regimens except for the well-studied ones. We constructed two EGFR variant libraries containing substitutions, deletions, or insertions using the saturation mutagenesis method. All the variants were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.